9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

400 Farmington Avenue, MC 6409
Farmington, CT 06032

Phone: 860-679-7894
Fax: 860-679-7896
Website: http://otc.uconn.edu/rd/portfolio/uconn-r-d-companies/

Carolyn Dealy, PhD, Scientific Advisor - dealy@nso2.uchc.edu

General Information
Chondrogenics Inc. is developing stem cell therapy for the treatment of osteoarthritis and the repair of damaged cartilage associated with diseased and damaged joints. Dr. Caroline Dealy, Associate Professor in the Center for Regenerative Medicine and Skeletal Development at the University of Connecticut Health Center, and colleagues have developed a novel process for producing substantially homogeneous populations of chondrogenic cells and earlier progenitor cells from stem cells, including induced pluripotent stem cells. Dr. Dealy is leading studies to evaluate the efficacy of cartilage repair by these cells in animals. A $75,000 prototype grant from the University of Connecticut’s Center for Science and Technology Commercialization has been used to develop the necessary animal models and to conduct initial assessment of cartilage repair. A $1.3 million grant from the State of Connecticut Stem Cell Program will be used for comprehensive preclinical characterization of this new therapy in preparation for eventual human clinical trials.